Lithium ameliorates altered glycogen synthase kinase-3 and behavior in a mouse model of Fragile X syndrome

Biochemical Pharmacology

Volumn 79, Issue 4, 2010, Pages 632-646

  Yuskaitis, Christopher J ^a   Mines, Marjelo A ^a   King, Margaret K ^a   Sweatt, J David ^b   Miller, Courtney A ^b   Jope, Richard S ^a  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^b University of Alabama at Birmingham   (United States)

Author keywords

Autism; FMR1; Glycogen synthase kinase 3; Lithium; MPEP

Indexed keywords

2 METHYL 6 (PHENYLETHYNYL)PYRIDINE; BRAIN DERIVED NEUROTROPHIC FACTOR; FRAGILE X MENTAL RETARDATION PROTEIN; GLYCOGEN SYNTHASE KINASE 3; LITHIUM CARBONATE; METABOTROPIC RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BRAIN CORTEX; CEREBELLUM; CHRONIC DRUG ADMINISTRATION; CONTROLLED STUDY; CORPUS STRIATUM; ENZYME INHIBITION; FRAGILE X SYNDROME; HIPPOCAMPUS; MALE; MAZE TEST; MOUSE; NONHUMAN; OPEN FIELD BEHAVIOR; PASSIVE AVOIDANCE; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION;

ANIMALS; AVOIDANCE LEARNING; DISEASE MODELS, ANIMAL; FRAGILE X MENTAL RETARDATION PROTEIN; FRAGILE X SYNDROME; GLYCOGEN SYNTHASE KINASE 3; LITHIUM CHLORIDE; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT;

EID: 71549145629     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bcp.2009.09.023     Document Type: Article

References (64)

1. Pieretti M., Zhang F.P., Fu Y.H., Warren S.T., Oostra B.A., Caskey C.T., et al. Absence of expression of the FMR-1 gene in fragile X syndrome. Cell 66 (1991) 817-822
2. Garber K., Smith K.T., Reines D., and Warren S.T. Transcription, translation and fragile X syndrome. Curr Opin Genet Dev 16 (2006) 270-275
3. Hagerman R.J., Ono M.Y., and Hagerman P.J. Recent advances in fragile X: a model for autism and neurodegeneration. Curr Opin Psychiatry 18 (2005) 490-496
4. Bakker C.E., Verheij C., Willemsen R., van der Helm R., Oerlemans F., Vermey M., et al. Fmr1 knockout mice: a model to study fragile X mental retardation. The Dutch-Belgian Fragile X Consortium. Cell 78 (1994) 23-33
5. Qin M., Kang J., and Smith C.B. Increased rates of cerebral glucose metabolism in a mouse model of fragile X mental retardation. Proc Natl Acad Sci USA 99 (2002) 15758-15763
6. Qin M., Kang J., and Smith C.B. A null mutation for Fmr1 in female mice: effects on regional cerebral metabolic rate for glucose and relationship to behavior. Neuroscience 135 (2005) 999-1009
7. Liu Z.H., and Smith C.B. Dissociation of social and nonsocial anxiety in a mouse model of fragile X syndrome. Neurosci Lett 454 (2009) 62-66
8. Mineur Y.S., Huynh L.X., and Crusio W.E. Social behavior deficits in the Fmr1 mutant mouse. Behav Brain Res 168 (2006) 172-175
9. Spencer C.M., Alekseyenko O., Serysheva E., Yuva-Paylor L.A., and Paylor R. Altered anxiety-related and social behaviors in the Fmr1 knockout mouse model of fragile X syndrome. Genes Brain Behav 4 (2005) 420-430
10. Spencer C.M., Graham D.F., Yuva-Paylor L.A., Nelson D.L., and Paylor R. Social behavior in Fmr1 knockout mice carrying a human FMR1 transgene. Behav Neurosci 122 (2008) 710-715
11. McBride S.M., Choi C.H., Wang Y., Liebelt D., Braunstein E., Ferreiro D., et al. Pharmacological rescue of synaptic plasticity, courtship behavior, and mushroom body defects in a Drosophila model of fragile X syndrome. Neuron 45 (2005) 753-764
12. Min W.W., Yuskaitis C.J., Yan Q., Sikorski C., Chen S., Jope R.S., et al. Elevated glycogen synthase kinase-3 activity in Fragile X mice: key metabolic regulator with evidence for treatment potential. Neuropharmacology 56 (2009) 463-472
13. Jope R.S. Anti-bipolar therapy: mechanism of action of lithium. Mol Psychiatry 4 (1999) 117-128
14. Phiel C.J., and Klein P.S. Molecular targets of lithium action. Annu Rev Pharmacol Toxicol 41 (2001) 789-813
15. Doble B.W., and Woodgett J.R. GSK-3: tricks of the trade for a multi-tasking kinase. J Cell Sci 116 (2003) 1175-1186
16. Jope R.S., and Johnson G.V. The glamour and gloom of glycogen synthase kinase-3. Trends Biochem Sci 29 (2004) 95-102
17. Force T., and Woodgett J.R. Unique and overlapping functions of GSK-3 isoforms in cell differentiation and proliferation and cardiovascular development. J Biol Chem 284 (2009) 9643-9647
18. Frame S., and Zheleva D. Targeting glycogen synthase kinase-3 in insulin signalling. Expert Opin Ther Targets 10 (2006) 429-444
19. Klein P.S., and Melton D.A. A molecular mechanism for the effect of lithium on development. Proc Natl Acad Sci USA 93 (1996) 8455-8459
20. Stambolic V., Ruel L., and Woodgett J.R. Lithium inhibits glycogen synthase kinase-3 activity and mimics wingless signalling in intact cells. Curr Biol 6 (1996) 1664-1668
21. De Sarno P., Li X., and Jope R.S. Regulation of Akt and glycogen synthase kinase-3 beta phosphorylation by sodium valproate and lithium. Neuropharmacology 43 (2002) 1158-1164
22. Jope R.S. Lithium and GSK-3: one inhibitor, two inhibitory actions, multiple outcomes. Trends Pharmacol Sci 24 (2003) 441-443
23. Dolen G., Osterweil E., Rao B.S., Smith G.B., Auerbach B.D., Chattarji S., et al. Correction of fragile X syndrome in mice. Neuron 56 (2007) 955-962
24. Yan Q.J., Rammal M., Tranfaglia M., and Bauchwitz R.P. Suppression of two major Fragile X Syndrome mouse model phenotypes by the mGluR5 antagonist MPEP. Neuropharmacology 49 (2005) 1053-1066
25. de Vrij F.M., Levenga J., van der Linde H.C., Koekkoek S.K., De Zeeuw C.I., Nelson D.L., et al. Rescue of behavioral phenotype and neuronal protrusion morphology in Fmr1 KO mice. Neurobiol Dis 31 (2008) 127-132
26. Liu F., Gong X., Zhang G., Marquis K., Reinhart P., and Andree T.H. The inhibition of glycogen synthase kinase 3beta by a metabotropic glutamate receptor 5 mediated pathway confers neuroprotection to Abeta peptides. J Neurochem 95 (2005) 1363-1372
27. O'Brien W.T., Harper A.D., Jové F., Woodgett J.R., Maretto S., Piccolo S., et al. Glycogen synthase kinase-3β haploinsufficiency mimics the behavioral and molecular effects of lithium. J Neurosci 24 (2004) 6791-6798
28. Su Y., Ryder J., Li B., Wu X., Fox N., Solenberg P., et al. Lithium, a common drug for bipolar disorder treatment, regulates amyloid-β precursor protein processing. Biochemistry 43 (2004) 6899-6908
29. Zhou R., Gray N.A., Yuan P., Li X., Chen J., Chen G., et al. The anti-apoptotic, glucocorticoid receptor cochaperone protein BAG-1 is a long-term target for the actions of mood stabilizers. J Neurosci 25 (2005) 4493-4502
30. Jope R.S. Lithium, the seminal GSK3 inhibitor. In: Martinez A., Castro A., and Medina M. (Eds). Glycogen synthase kinase 3 (GSK-3) and its inhibitors (2006), John Wiley and Sons, Inc. 223-242
31. Gould T.D., O'Donnell K.C., Picchini A.M., and Manji H.K. Strain differences in lithium attenuation of d-amphetamine-induced hyperlocomotion: a mouse model for the genetics of clinical response to lithium. Neuropsychopharmacology 32 (2007) 1321-1333
32. Dolen G., and Bear M.F. Role for metabotropic glutamate receptor 5 (mGluR5) in the pathogenesis of fragile X syndrome. J Physiol 586 (2008) 1503-1508
33. Berry-Kravis E., Hessl D., Coffey S., Hervey C., Schneider A., Yuhas J., et al. A pilot open label, single dose trial of fenobam in adults with fragile X syndrome. J Med Genet 46 (2009) 266-271
34. Davies S.P., Reddy H., Caivano M., and Cohen P. Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem J 351 (2000) 95-105
35. Berry-Kravis E., Sumis A., Hervey C., Nelson M., Porges S.W., Weng N., et al. Open-label treatment trial of lithium to target the underlying defect in fragile X syndrome. J Dev Behav Pediatr 29 (2008) 293-302
36. Monteggia L.M., Barrot M., Powell C.M., Berton O., Galanis V., Gemelli T., et al. Essential role of brain-derived neurotrophic factor in adult hippocampal function. Proc Natl Acad Sci USA 101 (2004) 10827-10832
37. Lauterborn J.C., Rex C.S., Kramar E., Chen L.Y., Pandyarajan V., Lynch G., et al. Brain-derived neurotrophic factor rescues synaptic plasticity in a mouse model of fragile X syndrome. J Neurosci 27 (2007) 10685-10694
38. Angelucci F., Aloe L., Jimenez-Vasquez P., and Mathe A.A. Lithium treatment alters brain concentrations of nerve growth factor, brain-derived neurotrophic factor and glial cell line-derived neurotrophic factor in a rat model of depression. Int J Neuropsychopharmacol 6 (2003) 225-231
39. Jacobsen J.P., and Mork A. The effect of escitalopram, desipramine, electroconvulsive seizures and lithium on brain-derived neurotrophic factor mRNA and protein expression in the rat brain and the correlation to 5-HT and 5-HIAA levels. Brain Res 1024 (2004) 183-192
40. Yasuda S., Liang M.H., Marinova Z., Yahyavi A., and Chuang D.M. The mood stabilizers lithium and valproate selectively activate the promoter IV of brain-derived neurotrophic factor in neurons. Mol Psychiatry 14 (2009) 51-59
41. Peier A.M., McIlwain K.L., Kenneson A., Warren S.T., Paylor R., and Nelson D.L. (Over)correction of FMR1 deficiency with YAC transgenics: behavioral and physical features. Hum Mol Genet 9 (2000) 1145-1159
42. Mineur Y.S., Sluyter F., de Wit S., Oostra B.A., and Crusio W.E. Behavioral and neuroanatomical characterization of the Fmr1 knockout mouse. Hippocampus 12 (2002) 39-46
43. Yan Q.J., Asafo-Adjei P.K., Arnold H.M., Brown R.E., and Bauchwitz R.P. A phenotypic and molecular characterization of the fmr1-tm1Cgr fragile X mouse. Genes Brain Behav 3 (2004) 337-359
44. Qin M., and Smith C.B. Unaltered hormonal response to stress in a mouse model of fragile X syndrome. Psychoneuroendocrinology 33 (2008) 883-889
45. Bilousova T.V., Dansie L., Ngo M., Aye J., Charles J.R., Ethell D.W., et al. Minocycline promotes dendritic spine maturation and improves behavioural performance in the fragile X mouse model. J Med Genet 46 (2009) 94-102
46. Hogg S. A review of the validity and variability of the elevated plus-maze as an animal model of anxiety. Pharmacol Biochem Behav 54 (1996) 21-30
47. Porsolt R.D., Brossard G., Hautbois C., and Roux S. Rodent models of depression: forced swimming and tail suspension behavioral despair tests in rats and mice. Curr Protoc Neurosci (2001) [Chapter 8:Unit 8 10A]
48. Jope R.S., and Roh M.S. Glycogen synthase kinase-3 (GSK3) in psychiatric diseases and therapeutic interventions. Curr Drug Targets 7 (2006) 1421-1434
49. Bear M.F., Huber K.M., and Warren S.T. The mGluR theory of fragile X mental retardation. Trends Neurosci 27 (2004) 370-377
50. Huber K.M., Gallagher S.M., Warren S.T., and Bear M.F. Altered synaptic plasticity in a mouse model of fragile X mental retardation. Proc Natl Acad Sci USA 99 (2002) 7746-7750
51. Nakamoto M., Nalavadi V., Epstein M.P., Narayanan U., Bassell G.J., and Warren S.T. Fragile X mental retardation protein deficiency leads to excessive mGluR5-dependent internalization of AMPA receptors. Proc Natl Acad Sci USA 104 (2007) 15537-15542
52. Anderson J.J., Bradbury M.J., Giracello D.R., Chapman D.F., Holtz G., Roppe J., et al. In vivo receptor occupancy of mGlu5 receptor antagonists using the novel radioligand [3H]3-methoxy-5-(pyridin-2-ylethynyl)pyridine). Eur J Pharmacol 473 (2003) 35-40
53. Chong Z.Z., Li F., and Maiese K. Group I metabotropic receptor neuroprotection requires Akt and its substrates that govern FOXO3a, Bim, and beta-catenin during oxidative stress. Curr Neurovasc Res 3 (2006) 107-117
54. Spinsanti P., De Vita T., Di Castro S., Storto M., Formisano P., Nicoletti F., et al. Endogenously activated mGlu5 metabotropic glutamate receptors sustain the increase in c-Myc expression induced by leukaemia inhibitory factor in cultured mouse embryonic stem cells. J Neurochem 99 (2006) 299-307
55. Giuffrida R., Musumeci S., D'Antoni S., Bonaccorso C.M., Giuffrida-Stella A.M., Oostra B.A., et al. A reduced number of metabotropic glutamate subtype 5 receptors are associated with constitutive homer proteins in a mouse model of fragile X syndrome. J Neurosci 25 (2005) 8908-8916
56. Ronesi J.A., and Huber K.M. Homer interactions are necessary for metabotropic glutamate receptor-induced long-term depression and translational activation. J Neurosci 28 (2008) 543-547
57. Ibarguen-Vargas Y., Surget A., Touma C., Palme R., and Belzung C. Multifaceted strain-specific effects in a mouse model of depression and of antidepressant reversal. Psychoneuroendocrinology 33 (2008) 1357-1368
58. Mohajeri M.H., Madani R., Saini K., Lipp H.P., Nitsch R.M., and Wolfer D.P. The impact of genetic background on neurodegeneration and behavior in seizured mice. Genes Brain Behav 3 (2004) 228-239
59. Bernardet M., and Crusio W.E. Fmr1 KO mice as a possible model of autistic features. ScientificWorldJournal 6 (2006) 1164-1176
60. 2+ signal transduction. J Biol Chem 267 (1992) 13361-13368
61. Fukumoto T., Morinobu S., Okamoto Y., Kagaya A., and Yamawaki S. Chronic lithium treatment increases the expression of brain-derived neurotrophic factor in the rat brain. Psychopharmacology (Berl) 158 (2001) 100-106
62. Prickaerts J., Moechars D., Cryns K., Lenaerts I., van Craenendonck H., Goris I., et al. Transgenic mice overexpressing glycogen synthase kinase 3beta: a putative model of hyperactivity and mania. J Neurosci 26 (2006) 9022-9029
63. Nielsen D.M., Derber W.J., McClellan D.A., and Crnic L.S. Alterations in the auditory startle response in Fmr1 targeted mutant mouse models of fragile X syndrome. Brain Res 927 (2002) 8-17
64. Tsaltas E., Kontis D., Boulougouris V., Papakosta V.M., Giannou H., Poulopoulou C., et al. Enhancing effects of chronic lithium on memory in the rat. Behav Brain Res 177 (2007) 51-60